Decoy Therapeutics Files S-1 for Resale of Up to 808,000 Shares
Decoy Therapeutics Inc. (DCOY) has filed an S-1 registration statement to allow for the resale of up to 808,000 shares of its common stock by C/M Capital Master Fund, LP. These shares are issuable under an equity line of credit (ELOC) agreement, through which Decoy Therapeutics may receive up to $5,000,000 in gross proceeds. A significant portion (50%) of these net proceeds will be used to redeem Series B Preferred Stock, with the balance allocated to working capital. The filing also provides background on the company's pre-clinical biotechnology focus, its recent merger and name change from Salarius Pharmaceuticals, and its status as a smaller reporting company that has recently resolved Nasdaq listing compliance issues.
Key Highlights
- Decoy Therapeutics Inc. filed an S-1 registration statement for the resale of up to 808,000 shares of common stock by C/M Capital Master Fund, LP.
- The shares are issuable under an equity line of credit (ELOC) established via a Securities Purchase Agreement.
- The company may receive up to $5,000,000 in aggregate gross proceeds from the sale of shares under the ELOC.
- 50% of net proceeds from the ELOC sales will be used to redeem Series B Preferred Stock, with the remainder for working capital.
- Decoy Therapeutics is a pre-clinical stage biotechnology company focused on peptide conjugate therapeutics.
- The company previously underwent a merger and name change from Salarius Pharmaceuticals, Inc. to Decoy Therapeutics Inc. on January 8, 2026.
- Decoy Therapeutics is currently a smaller reporting company and has faced Nasdaq minimum bid price compliance issues, which were resolved via a reverse stock split.
Price Impact
More from DCOY